当前位置:首页 » 翻译 
  • 匿名
关注:1 2013-05-23 12:21

求翻译:Except for biotechnology-derived products, an assessment of the impurities and degradants present in the drug substance and product should be included along with what is known of their potential pharmacologic and toxicologic effects. This assessment should form part of the justification for proposed impurity limits in the drug substance and product, and be appropriately cross-referenced to the quality documentation. The implications of any differences in the chirality, chemical form, and impurity profile between the compound used in the nonclinical studies and the product to be marketed should be discussed. For biotechnology-derived products, comparability of material used in nonclinical studies, clinical studies, and proposed for marketing should be assessed. If a drug product includes a novel excipient, an assessment of the information regarding its safety should be provided.是什么意思?

待解决 悬赏分:1 - 离问题结束还有
Except for biotechnology-derived products, an assessment of the impurities and degradants present in the drug substance and product should be included along with what is known of their potential pharmacologic and toxicologic effects. This assessment should form part of the justification for proposed impurity limits in the drug substance and product, and be appropriately cross-referenced to the quality documentation. The implications of any differences in the chirality, chemical form, and impurity profile between the compound used in the nonclinical studies and the product to be marketed should be discussed. For biotechnology-derived products, comparability of material used in nonclinical studies, clinical studies, and proposed for marketing should be assessed. If a drug product includes a novel excipient, an assessment of the information regarding its safety should be provided.
问题补充:

  • 匿名
2013-05-23 12:26:38
为生物产品,除杂质和 degradants 中的原料药和产品的评估应包括随什么已知其潜在的影响毒理和药理代理商。此评估应建议的杂质限制中的原料药和产品,理由的一部份,并会适当地互相参照的质量文件。应讨论任何在手、 化学形态和杂质配置文件用于在非临床研究和产品销售的复合之间的差异的影响。生物产品,应评估材料用于非临床研究、 临床研究,并提出了市场营销的可比性。如果药物产品包括新型赋形剂,应提供评估其安全有关的信息。
 
 
网站首页

湖北省互联网违法和不良信息举报平台 | 网上有害信息举报专区 | 电信诈骗举报专区 | 涉历史虚无主义有害信息举报专区 | 涉企侵权举报专区

 
关 闭